Douglas Matthew Brown net worth and biography

Douglas Brown Biography and Net Worth

Prior to joining NeoGenomics, Mr. Brown was Senior Managing Director with SVB Leerink with significant expertise in the oncology diagnostic sector. During his career, he has advised clients in over 100 successful M&A and Corporate Financing transactions. Doug advised General Electric on the sale of Clarient, and recently advised NeoGenomics on the acquisition of Genoptix and the oncology assets of Human Longevity. Mr. Brown earned his MBA from the Fuqua School of Business at Duke University and received his undergraduate business degree from the University of Texas at Austin.

How do I contact Douglas Matthew Brown?: The corporate mailing address for Mr. Brown and other NeoGenomics executives is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. NeoGenomics can also be reached via phone at (239) 768-0600 and via email at [email protected]. Learn More on Douglas Matthew Brown's contact information.
Has Douglas Matthew Brown been buying or selling shares of NeoGenomics?: Douglas Matthew Brown has not been actively trading shares of NeoGenomics during the last quarter. Most recently, Douglas Matthew Brown sold 33,334 shares of the business's stock in a transaction on Friday, November 26th. The shares were sold at an average price of $36.85, for a transaction totalling $1,228,357.90. Learn More on Douglas Matthew Brown's trading history.
Who are NeoGenomics' active insiders?: NeoGenomics' insider roster includes (), Douglas Brown (Insider), George Cardoza (Insider), Bruce Crowther (Director), Mark Mallon (CEO), Kathryn McKenzie (CFO), and Robert Shovlin (Insider). Learn More on NeoGenomics' active insiders.
Are insiders buying or selling shares of NeoGenomics?: During the last year, insiders at the medical research company sold shares 2 times. They sold a total of 5,256 shares worth more than $87,784.43. The most recent insider tranaction occured on February, 15th when General Counsel Alicia C Olivo sold 2,587 shares worth more than $38,701.52. Insiders at NeoGenomics own 1.3% of the company. Learn More about insider trades at NeoGenomics.
Information on this page was last updated on 2/15/2024.

Douglas Matthew Brown Insider Trading History at NeoGenomics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/26/2021	Sell	33,334	$36.85	$1,228,357.90
11/23/2021	Sell	33,333	$37.19	$1,239,654.27

Douglas Matthew Brown Buying and Selling Activity at NeoGenomics

NeoGenomics Company Overview

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Today's Range

Now: $13.77

$13.62

$14.09

50 Day Range

MA: $15.13

$13.68

$16.79

2 Week Range

Now: $13.77

$11.03

$21.22

Volume

913,517 shs

Average Volume

904,194 shs

Market Capitalization

$1.76 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.1

AI “wealth window” is closing soon!

From Paradigm Press | Ad

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…